Hikal Ltd (HIKAL) Q2FY27 Concall Summary - Sep-2026 Qtr
Key Takeaways
- Management reiterated full-year guidance for mid-teens revenue growth and substantially improved profitability, expecting a significantly better H2.
- A new multi-year, high-margin CDMO contract in crop protection will add INR 50-75 crores in peak annual revenue, signaling a strategic business mix shift.
- A US FDA re-inspection is anticipated by the end of FY27; successful clearance would unlock an estimated INR 150 crores in annualized revenue.
Performance Overview
- Delivered revenue and EBITDA growth compared to the previous year, though profitability was impacted by higher raw material prices.
- The Pharmaceutical business showed signs of recovery in its established API portfolio and sustained execution in the CDMO business.
- The Crop Protection business navigated a challenging environment with pricing pressure, but secured a significant multi-year CDMO contract with a European agrochemical major.
- Progress was made on the quality remediation program at the Bengaluru facility, receiving a GMP compliance certificate from Swissmedic.
- Emerging businesses like Animal Health and Specialty Ingredients showed progress, with the latter commencing commercial production at its new Panoli facility.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.
Tone & Disclosure
Log in to Stocksigma to read the Tone & Disclosure section of this summary.